Self-Adaptive Antibacterial Scaffold with Programmed Delivery of Osteogenic Peptide and Lysozyme for Infected Bone Defect Treatment

ACS Appl Mater Interfaces. 2023 Jan 11;15(1):626-637. doi: 10.1021/acsami.2c19026. Epub 2022 Dec 21.

Abstract

Bone defects caused by disease or trauma are often accompanied by infection, which severely disrupts the normal function of bone tissue at the defect site. Biomaterials that can simultaneously reduce inflammation and promote osteogenesis are effective tools for addressing this problem. In this study, we set up a programmed delivery platform based on a chitosan scaffold to enhance its osteogenic activity and prevent implant-related infections. In brief, the osteogenic peptide sequence (YGFGG) was modified onto the surface of cowpea chlorotic mottle virus (CCMV) to form CCMV-YGFGG nanoparticles. CCMV-YGFGG exhibited good biocompatibility and osteogenic ability in vitro. Then, CCMV-YGFGG and lysozyme were loaded on the chitosan scaffold, which exhibited a good antibacterial effect and promoted bone regeneration for infected bone defect treatment. As a delivery platform, the scaffold showed staged release of lysozyme and CCMV-YGFGG, which facilitates the regeneration of infected bone defects. Our study provides a novel and promising strategy for the treatment of infected bone defects.

Keywords: antibacterial; cowpea chlorotic mottle virus; infected bone defect; osteogenesis; osteogenic peptide.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Bone Regeneration
  • Chitosan* / pharmacology
  • Muramidase / pharmacology
  • Osteogenesis*
  • Peptides / pharmacology
  • Tissue Scaffolds

Substances

  • Chitosan
  • Muramidase
  • Anti-Bacterial Agents
  • Peptides